Abstract
On February 3–4, 2009, a DIA Workshop was held to review and discuss comparability challenges and issues for biotechnology-derived pharmaceuticals. The workshop was held in the Washington, DC, area and was attended by representatives from the FDA and biotech and pharmaceutical industries. The expectation was to develop a consensus on which data are necessary to provide assurance of comparability for manufacturing changes made to biotechnology products during different stages of development or postmarketing. Numerous case studies were reviewed and discussed to build on best practices and recognize successful approaches to comparability.
Keywords
Get full access to this article
View all access options for this article.
References
1.International Conference on Harmonization.
Guidance for industry, Q5E: comparability of biotechnological/biological products subject to changes in their manufacturing process . 2005 . http://www.fda.gov/RegulatoryInformation/Guidances/ucm128059.htm#f4.
2.Food and Drug Administration.
Guidance for industry: changes to an approved application for specified biotechnology and specified synthetic biological products . 1997 . http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM124805.pdf.
3.Title 21 Code of Federal Regulations (21 CFR) , sections 314.70 and 601.12.
4.
Bauman
A.
Early development of therapeutic biologics—pharmacokinetics . Curr Drug Metab.
2006 :7 :15 –21 .
5.International Conference on Harmonization.
Guidance for industry: Q6B specifications: test procedures and acceptance criteria for biotechnological/biological products . http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073488.pdf.
6.
Reynolds
DW
Available guidance and best practices for conducting forced degradation studies . Pharm Tech.
2002 ;48 –56 . http://pharmtech.findpharma.com/pharmtech/data/articlestandard//pharmtech/072002/9668/article.pdf.
7.International Conference on Harmonization.
Guidance for industry: Q1A(R2) stability testing of new drug substances and products . 2001 . http://www.fda.gov/RegulatoryInformation/Guidances/ucm128179.htm.
8.International Conference on Harmonization.
Guidance for industry: Q5C quality of biotechnological products: stability testing of biotech nological/biological products . 1996 . http://www.fda.gov/downloads/Regulatorylnformation/Guidances/UCM129109.pdf.
9.
Manning
MC
Stability of protein pharmaceuticals . Pharm Res.
1989 ;6 : 903 –918 .
10.
Jenkins
N
Parekh
RB
James
DC
. Getting the glycosylation right: implications for the biotechnology industry . Nat Biotechnol.
1996 ;14 : 975 –981 .
11.
Sheeley
DM
Merrill
BM
Taylor
LCE
. Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal α-linked galactose . Anal Biochem.
1997 :247 :102 –110 .
12.
Lim
A
Reed-Bogan
A
Harmon
BJ
. Glycosylation profiling of a therapeutic recombinant monoclonal antibody with two N-linked glycosylation sites using liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer . Anal Biochem.
2008 ;375 : 163 –172 .
13.Vectibix, FDA Review , Application Number 125147, approval September 27, 2006. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125147s0000TOC.cfm.
14.Vectibix, European Public Assessment Report , CHMP, 2007. http://www.ema.europa.eu/humandocs/PDFs/EPAR/vectibix/H-741-en1.pdf.
15.
Lenz
HJ
. Anti-EGFr mechanism of action: antitumor effect and underlying cause of adverse events . Oncology.
2006 ;20 (5 ):5 –13 .
16.
Giusti
RM
Shastri
K
Pilaro
AM
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens . Clin Cancer Res.
2008 :14 :1296–1302.
17.
Freeman
DJ
. Review: safety and efficacy of panitumumab in the treatment of metastatic colorectal cancer . Clin Med Ther.
2009 :1 :633 –645 .
18.
Roopenian
DC
Akilesh
S.
FcRn: the neonatal Fc receptor comes of age . Nat Rev Immunol.
2007 ;7 : 715 –725 .
19.
Joshi
A
Bauer
R
Kuebler
P
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis . J Clin Pharmacol.
2006 ;46 : 10 –20 .
20.
Millward
TA
Heitzmann
M
Bill
K
Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice . Biologicals.
2008 ;36 : 41 –47 .
21.Nplate (Romiplostim). FDA Summary Basis of Approval. 2008 . http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125268s000_sumR.pdf.
22.
Cerosimo
RJ
. Romiplostim in chronic immune thrombocytopenic purpura . Clin Ther.
2009 ;31 : 1887 –1907 .
23.
Newland
A.
Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura . Eur J Haematol
2009 ;71 (Suppl. ):20 –25 .
24.Benefix (Coagulation Factor IN [recombinant]).
FDA Summary Basis of Approval . 1997 . http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm058970.pdf.
25.
Pipe
SW
. Recombinant clotting factors . Thromb Haemost.
2008 ;99 : 840 –850 .
26.
King
KM
Younes
A.
Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma . Expert Rev Anticancer Ther.
2001 ;1 : 177 –186 .
27.
Tastetter
W
Molina
A
White
CA
. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases . Ann Rev Med.
2004 :55 :477 –503 .